Proton beam therapy (PBT) is a critical treatment modality for
head and neck squamous cell carcinoma (
HNSCC). However, not much is known about
drug combinations that may improve the efficacy of PBT. This study aimed to test the feasibility of a three-dimensional (3D)
tumor-spheroid-based high-throughput screening platform that could assess cellular sensitivity against PBT. Spheroids of two
HNSCC cell lines-Fadu and Cal27-cultured with a mixture of
Matrigel were arrayed on a 384-pillar/well plate, followed by exposure to graded doses of
protons or targeted drugs including
olaparib at various concentrations.
Calcein staining of
HNSCC spheroids revealed a dose-dependent decrease in cell viability for
proton irradiation or multiple targeted drugs, and provided quantitative data that discriminated the sensitivity between the two
HNSCC cell lines. The combined effect of
protons and
olaparib was assessed by calculating the combination index from the survival rates of 4 × 4 matrices, showing that Cal27 spheroids had greater synergy with
olaparib than Fadu spheroids. In contrast,
adavosertib did not synergize with
protons in both spheroids. Taken together, we demonstrated that the 3D pillar/well array platform was a useful tool that provided rapid, quantitative data for evaluating sensitivity to PBT and
drug combinations. Our results further supported that administration of the combination of PBT and
olaparib may be an effective treatment strategy for
HNSCC patients.